Date: 2014-03-17
Type of information: Results
phase: 2a
Announcement: results
Company: Ipsen (France)
Product: Dysport® (abobotulinumtoxin A)
Action
mechanism: protein.
Disease: Neurogenic Detrusor Overactivity (NDO)
Therapeutic area: Neurological diseases - CNS diseases
Country:
Trial details:
Latest
news: * On March 18, 2014, Ipsen has announced positive results from its phase IIa clinical trial assessing Dysport® in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics. Results show that treatment with Dysport® was associated with a mean reduction from baseline of urinary incontinence episodes greater than 75%, 12 weeks after the injection, regardless of how the drug is administered. These results were achieved with a single dose of Dysport® 750 Units injected in either 15 or 30 sites in the detrusor muscle. Efficacy was confirmed by improvement in urodynamic parameters and quality of life. The safety profile observed in the study is consistent with the safety profile expected in this indication.
